secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001193125-24-196040
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno reports Q2 2024 net loss of $21.9M; NDA for DCCR in PWS submitted to FDA
-------------------------------------------------------------------------------

- NDA for Diazoxide Choline Extended-Release (DCCR) for Prader-Willi Syndrome with hyperphagia submitted to FDA.
- Cash, cash equivalents and marketable securities of $294.6M as of June 30, 2024.
- Net loss of $21.9M ($0.57 per share) for Q2 2024 vs. $8.5M ($0.81 per share) in Q2 2023.
- R&D expense $12.3M (Q2 2024) up from $5.1M (Q2 2023) due to NDA submission and launch prep.
- Closed $158.7M public offering of 3.45M shares at $46.00 each; BT designation for DCCR granted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312524196040/0001193125-24-196040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312524196040/d892011d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-196040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer